Compare Charles River Laboratories Intl. Inc (CRL) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $228.92 (market cap $11.14B), while Vanguard Short Term Corporate Bond ETF trades at $78.71. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| CRL | VCSH | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Fixed Income |
52-Week High | $233.60 | $80.20 |
52-Week Low | $145.57 | $78.45 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
VCSH trades at $78.45, down 0.2% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF maintains consistent dividend distributions, with recent payouts of $0.29-$0.30 per share. Media coverage highlights VCSH's competitive yield advantage over similar short-term bond ETFs and its appeal for income-focused investors seeking corporate bond exposure with low expense ratios.
The outlook remains cautious given the Federal Reserve's indication that rate cuts are unlikely in 2026, which may pressure short-term bond performance. VCSH offers higher yields than treasury alternatives but carries additional credit risk. Institutional activity shows mixed positioning, with some firms increasing stakes while others reduce exposure amid interest rate uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
